ZA946887B - Novel proteins/polypeptides and cotransfection plasmics and live recombinant carriers therefor - Google Patents
Novel proteins/polypeptides and cotransfection plasmics and live recombinant carriers thereforInfo
- Publication number
- ZA946887B ZA946887B ZA946887A ZA946887A ZA946887B ZA 946887 B ZA946887 B ZA 946887B ZA 946887 A ZA946887 A ZA 946887A ZA 946887 A ZA946887 A ZA 946887A ZA 946887 B ZA946887 B ZA 946887B
- Authority
- ZA
- South Africa
- Prior art keywords
- plasmics
- cotransfection
- polypeptides
- novel proteins
- live recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9319212A GB2282601B (en) | 1993-09-16 | 1993-09-16 | Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA946887B true ZA946887B (en) | 1995-06-27 |
Family
ID=10742112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA946887A ZA946887B (en) | 1993-09-16 | 1994-09-07 | Novel proteins/polypeptides and cotransfection plasmics and live recombinant carriers therefor |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0720654A1 (en) |
JP (1) | JPH09509562A (en) |
KR (1) | KR960705047A (en) |
AU (1) | AU7615894A (en) |
BR (1) | BR9407507A (en) |
CA (1) | CA2171869A1 (en) |
GB (2) | GB2316681B (en) |
NO (1) | NO961086L (en) |
WO (1) | WO1995007987A2 (en) |
ZA (1) | ZA946887B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2724385B1 (en) * | 1994-08-29 | 1996-12-13 | Rhone Merieux | FELINE INFECTIOUS PERITONITIS VACCINE. |
FR2741806B1 (en) * | 1995-11-30 | 1998-02-20 | Rhone Merieux | RECOMBINANT LIVING VACCINE BASED ON TYPE 1 FELINE HERPESVIRUS, PARTICULARLY AGAINST FELIN INFECTIOUS PERITONITIS |
WO1998001570A2 (en) * | 1996-07-05 | 1998-01-15 | Vanderbilt University | Mutated antibody-dependent infection enhancing domains of hiv |
FR2751223B1 (en) | 1996-07-19 | 1998-12-04 | Rhone Merieux | FELIN POLYNUCLEOTIDE VACCINE FORMULA |
CN1223605C (en) * | 2003-05-16 | 2005-10-19 | 中国科学院微生物研究所 | Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof |
CN113321714B (en) * | 2020-02-28 | 2022-12-09 | 深圳市亚辉龙生物科技股份有限公司 | Recombinant N protein of SARS-CoV-2 and its preparation and purification method |
US20230331782A1 (en) * | 2020-09-08 | 2023-10-19 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Reducing Risk of Vaccine-Enhanced Disease |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL76751A (en) * | 1984-11-01 | 1991-04-15 | American Home Prod | Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies |
EP0264979A1 (en) * | 1986-09-05 | 1988-04-27 | Duphar International Research B.V | New antigenically active proteins and peptides, and feline infectious peritonitis virus (FIPV) vaccines |
CA2005291C (en) * | 1988-12-30 | 1999-01-26 | Beverly Dale | Feline infectious peritonitis virus diagnostic tools |
HUT54733A (en) * | 1989-07-12 | 1991-03-28 | Duphar Int Res | Process for producing new, antigenically active proteins and peptides, as well as feline infectious peritonitis virus (fipv) vaccines |
NZ240558A (en) * | 1990-11-14 | 1994-11-25 | Smithkline Beecham Corp | Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease |
WO1993023423A1 (en) * | 1992-05-08 | 1993-11-25 | Smithkline Beecham Corporation | Canine coronavirus s gene and uses therefor |
JPH07504897A (en) * | 1992-02-18 | 1995-06-01 | パーヘリオン コーポレーション | Feline infectious peritonitis vaccine and preparation method |
WO1993023421A1 (en) * | 1992-05-08 | 1993-11-25 | Smithkline Beecham Corporation | Universal coronavirus vaccine |
-
1993
- 1993-09-16 GB GB9722558A patent/GB2316681B/en not_active Expired - Fee Related
- 1993-09-16 GB GB9319212A patent/GB2282601B/en not_active Expired - Fee Related
-
1994
- 1994-09-07 ZA ZA946887A patent/ZA946887B/en unknown
- 1994-09-07 CA CA002171869A patent/CA2171869A1/en not_active Abandoned
- 1994-09-07 WO PCT/EP1994/002990 patent/WO1995007987A2/en not_active Application Discontinuation
- 1994-09-07 EP EP94926246A patent/EP0720654A1/en not_active Withdrawn
- 1994-09-07 BR BR9407507A patent/BR9407507A/en not_active Application Discontinuation
- 1994-09-07 JP JP7508961A patent/JPH09509562A/en active Pending
- 1994-09-07 KR KR1019960701359A patent/KR960705047A/en not_active Application Discontinuation
- 1994-09-07 AU AU76158/94A patent/AU7615894A/en not_active Abandoned
-
1996
- 1996-03-15 NO NO961086A patent/NO961086L/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB2316681B (en) | 1998-04-15 |
CA2171869A1 (en) | 1995-03-23 |
WO1995007987A3 (en) | 1995-06-22 |
GB2282601A (en) | 1995-04-12 |
GB9319212D0 (en) | 1993-11-03 |
EP0720654A1 (en) | 1996-07-10 |
NO961086L (en) | 1996-05-09 |
JPH09509562A (en) | 1997-09-30 |
GB2316681A (en) | 1998-03-04 |
KR960705047A (en) | 1996-10-09 |
AU7615894A (en) | 1995-04-03 |
NO961086D0 (en) | 1996-03-15 |
GB9722558D0 (en) | 1997-12-24 |
BR9407507A (en) | 1997-01-07 |
WO1995007987A2 (en) | 1995-03-23 |
GB2282601B (en) | 1998-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0742793A4 (en) | Bcl-2-associated proteins | |
AU5283793A (en) | Recombinant specific binding protein | |
DE4393381T1 (en) | Peptides | |
IL137129A0 (en) | Labeled chemotactic peptides | |
PL309778A1 (en) | Novel peptides | |
AU1648092A (en) | Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins | |
AU6428890A (en) | Therapeutic peptides and proteins | |
EP0448099A3 (en) | Novel peptides | |
EP0696204A4 (en) | Recombinant fowlpox viruses and uses thereof | |
ZA895137B (en) | Novel peptides | |
GB9414833D0 (en) | Polypeptide | |
ZA9410217B (en) | Recombinant human thymopoietin proteins and uses therefor. | |
ZA946887B (en) | Novel proteins/polypeptides and cotransfection plasmics and live recombinant carriers therefor | |
EP0690912A4 (en) | Recombinant avian adenovirus vector | |
GB9314802D0 (en) | Modified proteins | |
ZA931203B (en) | A recombinant polypeptide | |
IL108353A0 (en) | Novel peptides | |
DE69427363D1 (en) | Platelet-inhibiting peptides | |
ZA931299B (en) | Novel peptides | |
GB9412147D0 (en) | Recombinant binding proteins and peptides | |
GB9507442D0 (en) | Recombinant specific binding protein | |
GB9022760D0 (en) | Dna sequence and polypeptide | |
GB9122330D0 (en) | Dna sequence and polypeptide | |
AU5939994A (en) | Linear peptides and uses thereof | |
ZA938572B (en) | Improved recombinant protein production |